Amgen reported strong sequential revenue growth, raised its full-year earnings guidance, and announced positive Phase III results for Denosumab in breast cancer patients. Additionally, the strategic partnership with GlaxoSmithKline to commercialize Denosumab internationally enhances its market potential. These developments, along with managementâ€™s optimistic outlook, are likely to positively impact the stock price in the short term.

[1]